Philips (ENXTAM:PHIA) Stock Looks Cheap Following A 37% Three Year Gain
Koninklijke Philips stock has delivered a 37.0% gain over the past three years, yet recent share price softness and a high overall value score suggest the market may still be treating it as cheaper than its fundamentals imply.
- Over the past three years, the 37.0% return points to solid shareholder gains despite a mixed shorter term track record.
- The recent update on earnings and the agreement with Senzime can support expectations for future profitability, while ongoing legal proceedings linked to the 2021 product recall remain a key overhang affecting how investors price that progress.
- Koninklijke Philips screens as undervalued on most metrics, with a 5 out of 6 value score that signals the broader checks lean cheap rather than expensive.
For investors, the debate is whether that high value score and longer term return record are enough to argue that Koninklijke Philips still trades at a discount despite recent setbacks in the share price.
Is Koninklijke Philips a Bargain on Earnings?
The P/E ratio is a useful way to look at Koninklijke Philips because earnings remain a core focus for many investors in the medical equipment sector.
Koninklijke Philips trades on a P/E of about 20.1x, compared with a medical equipment industry average of around 24.3x and a peer group average close to 22.5x. On this snapshot, the stock changes hands at a lower earnings multiple than both its wider industry and more direct peers. That points to the market pricing Philips at a discount relative to the earnings investors are currently paying for elsewhere in the sector.
Despite the recent lift in sentiment after the Q2 2026 earnings update and improved outlook, the P/E multiple still sits below these benchmarks. For investors comparing options across medical equipment stocks, this gap suggests the market price of Koninklijke Philips does not fully reflect its earnings profile when set against sector norms.
On the P/E multiple alone, Koninklijke Philips stock currently appears undervalued compared with its industry and peer averages.
See what the numbers say about this price — find out in our valuation breakdown.
The Koninklijke Philips Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the valuation puzzle around Koninklijke Philips leaves off by spelling out which earnings, growth and margin paths would need to play out for the stock to be worth materially more or materially less than today’s price. Each one connects its number to a clear view on how Koninklijke Philips' growth, profitability and key risks could evolve, giving you something concrete to revisit as new information emerges.
Community views on Koninklijke Philips split into two clear camps that see very different risk and reward profiles from here.
Bull case: 18% undervalued
"Structural growth in chronic cardiovascular and oncology care, combined with Philips leadership in AI-powered ultrasound and radiation therapy planning, could deepen account penetration and service attachment rates..."
Read the full Bull Case to see why Koninklijke Philips could be undervalued
Bear case: roughly fairly valued
"Escalating and potentially prolonged tariffs, alongside localization pressures and Section 232 type trade measures, risk offsetting recent productivity gains and could cap future gross margin expansion even if revenue grows..."
Read the full Bear Case to see why Koninklijke Philips could be overvalued
Do you think there's more to the story for Koninklijke Philips? Head over to our Community to see what others are saying!
The Bottom Line
For Koninklijke Philips, the core question is whether the current discount on earnings is compensation for real risk or a mispricing that could close over time. Market multiples point to the stock trading on the cheap side compared with sector peers, and the broader valuation checks lean in the same direction. The legal overhang from the 2021 product recall sits at the heart of this gap. For now, the key issue for investors is whether that risk gradually clears in a way that lets the P/E multiple move closer to industry norms, or whether it proves to be a more lasting drag on the valuation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com